Truist raises Genmab stock price target to $49 on Merus acquisition

Genmab A/S is acquiring Merus N.V. for approximately $8 billion in an all-cash transaction, funded by cash and $5.5 billion in debt, primarily to secure full rights to petosemtamab, an EGFR × LGR5 bispecific antibody in Phase 3 trials for head and neck cancer. Truist Securities, raising its price target to $49, projects petosemtamab could generate $1.8 billion in topline revenue by 2029, strategically offsetting anticipated royalty declines from Genmab’s Darzalex product and strengthening its long-term pipeline, a sentiment reflected in other analyst price target adjustments.

Analysis

Genmab A/S (GMAB) is undertaking a significant strategic acquisition of Merus (MRUS) for approximately $8 billion in an all-cash transaction, a move broadly viewed as positive by the analyst community. The core rationale is to secure full rights to petosemtamab, a bispecific antibody in two Phase 3 trials for head and neck cancer. This asset is projected by Truist Securities to contribute approximately $1.8 billion in topline revenue by 2029 ($1.45 billion risk-adjusted), strategically positioning Genmab to offset the anticipated decline in royalties from its key product, Darzalex. The deal, funded by cash and $5.5 billion in non-convertible debt, has prompted several analyst upgrades; Truist raised its price target to $49.00 from $46.00, while H.C. Wainwright and Leerink Partners also increased their targets, all maintaining Buy ratings. This sentiment is supported by Genmab's strong underlying fundamentals, including a 94.54% gross profit margin and a 66.94% stock return over the past six months. Further positive pipeline developments, such as promising Phase 2 data for epcoritamab, add to the company's favorable outlook, although the full financial impact of the Merus acquisition hinges on clinical trial success with topline results not expected until 2026 or later.

Key Decisions for Investors

• Investors should view the Merus acquisition as a strategic long-term positive that directly addresses Genmab's future revenue concentration risk from Darzalex, justifying the largely bullish analyst consensus.
• It is crucial to monitor the company's increased leverage following the issuance of $5.5 billion in debt to fund the deal, as well as the clinical progress of petosemtamab, given that its success is the primary driver of the acquisition's value.
• Considering the stock's significant 66.94% appreciation over the past six months, investors should assess if the positive outlook from this acquisition is already priced in, and be mindful of execution risk with trial data not expected until 2026 or later.